Medtronic Completes $650M Acquisition of SPR Therapeutics to Expand Pain Management Portfolio

The Quick Take

• Medtronic has completed its $650 million acquisition of SPR Therapeutics, adding peripheral nerve stimulation to its chronic pain management portfolio
• The deal extends Medtronic's neuromodulation franchise with a non-opioid pain therapy that avoids the dependency risks of pharmacological treatments
• The acquisition continues Medtronic's strategy of bolt-on deals in high-growth medical device subsegments to supplement organic R&D growth

Medtronic's $650 million acquisition of SPR Therapeutics closes a strategic gap in its neuromodulation portfolio by adding peripheral nerve stimulation — a non-opioid chronic pain management modality with a growing clinical evidence base. The chronic pain management market is one of medtech's highest-growth subsegments, driven by the opioid crisis response and the shift toward device-based therapies that avoid dependency risk while providing sustained pain relief. SPR Therapeutics targets peripheral nerve stimulation specifically, a less invasive alternative to spinal cord stimulation that Medtronic already sells through its existing platforms, creating natural synergies in the sales force's established hospital and pain clinic relationships.

The $650 million price point positions SPR Therapeutics in the mid-market acquisition range Medtronic has favored in recent years, signaling preference for bolt-on acquisitions that fit existing commercial infrastructure rather than transformative deals requiring integration of entirely separate business operations. For Boston Scientific and Abbott, which compete in neuromodulation, the acquisition signals Medtronic's determination to defend and expand its position as the peripheral nerve stimulation segment attracts renewed clinical interest and insurance reimbursement. Private equity-backed medical device companies with pain management technologies may see valuation uplift as Medtronic signals strategic interest in the adjacent space.

Watch Medtronic's next quarterly earnings call for any disclosure of SPR Therapeutics' revenue contribution and integration timeline milestones. Commentary on sales force training completion and the clinical trial pipeline for SPR's technology in new pain indications will signal how quickly the deal contributes to revenue growth. The macro variable is US healthcare reimbursement for peripheral nerve stimulation procedures: if CMS expands reimbursement codes to cover additional pain management device applications, Medtronic's investment thesis for SPR is significantly validated and the payback period accelerates materially. International submissions in Europe and Japan will extend the addressable market.

Synthesized from 1 source.